Company profile
PROTHENA CORP PUBLIC LTD CO
NASDAQ:PRTABiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BIRTAMIMAB | phase3 | — | 6 | completed, terminated |
| CORAMITUG | phase1 | — | 1 | terminated |
| IMAPRELIMAB | phase1 | — | 2 | no active trials |
| PRASINEZUMAB | phase1 | — | 2 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03336580 | phase1 | terminated | 2018-04-05 | 2020-07-23 | Prothena Biosciences Limited | A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis |
| NCT04973137 | phase3 | terminated | 2021-08-30 | 2025-04-02 | Prothena Biosciences Ltd. | A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis |
| NCT02157714 | phase1 | completed | 2014-06-01 | 2016-09-01 | Prothena Biosciences Limited | Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease |
| NCT02630901 | phase1 | completed | 2016-03-17 | 2018-02-28 | Prothena Biosciences Limited | Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis |
| NCT02613182 | phase2 | terminated | 2016-02-01 | 2018-05-01 | Prothena Biosciences Ltd. | Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis |
FDA applications (0)
No records yet.